Patents by Inventor Kirk R. Gustafson
Kirk R. Gustafson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090197940Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.Type: ApplicationFiled: March 12, 2009Publication date: August 6, 2009Applicant: The United States of America, as repersented by the Secretary, Department of Health and Human ServInventors: Michael R. Boyd, Kirk R. Gustafson
-
Patent number: 7521475Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.Type: GrantFiled: February 13, 2007Date of Patent: April 21, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson
-
Patent number: 7205334Abstract: A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.Type: GrantFiled: July 24, 2003Date of Patent: April 17, 2007Assignee: United States of America, represented by the Secretary, Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson
-
Patent number: 7144918Abstract: The present invention provides a compound of the formula (I). The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.Type: GrantFiled: July 24, 2001Date of Patent: December 5, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Charles L. Cantrell
-
Patent number: 6987096Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.Type: GrantFiled: November 13, 1997Date of Patent: January 17, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
-
Patent number: 6774141Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: May 20, 1998Date of Patent: August 10, 2004Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman
-
Publication number: 20040087566Abstract: The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(═O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9a is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent.Type: ApplicationFiled: June 11, 2003Publication date: May 6, 2004Inventors: Michael R Boyd, Kirk R Gustafson, Charles L Cantrell
-
Patent number: 6673830Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: June 22, 2001Date of Patent: January 6, 2004Assignees: The United States of America as represented by the Secretary of Health and Human Services, The Board of Trustees of the University of IllinoisInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
-
Publication number: 20020086898Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: ApplicationFiled: June 22, 2001Publication date: July 4, 2002Inventors: Michael R. Boyd, John H. Cardellina, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
-
Patent number: 6245737Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: August 19, 1998Date of Patent: June 12, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
-
Patent number: 5998587Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences ending such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.Type: GrantFiled: November 13, 1997Date of Patent: December 7, 1999Assignee: The United States of America, represented by the Secretary of the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
-
Patent number: 5962653Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: November 13, 1997Date of Patent: October 5, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson
-
Patent number: 5869522Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: May 31, 1995Date of Patent: February 9, 1999Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael R. Boyd, John H. Cardelina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parsons, Lewis Pannell, James B. McMahon, Gordon M. Cragg
-
Patent number: 5859049Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: May 24, 1996Date of Patent: January 12, 1999Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of IllinoisInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto
-
Patent number: 5843882Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: April 27, 1995Date of Patent: December 1, 1998Assignee: The United States of America as Represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
-
Patent number: 5821081Abstract: The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.Type: GrantFiled: April 26, 1996Date of Patent: October 13, 1998Assignee: The United States of Americaa as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Robert H. Shoemaker, James B. McMahon
-
Patent number: 5783598Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: March 8, 1996Date of Patent: July 21, 1998Assignee: The United States of America as represented by the Secretary of the Department of Health and Human SevicesInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parson, Lewis Pannell, James B. McMahon, Gordon M. Cragg
-
Patent number: 5672607Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: January 29, 1993Date of Patent: September 30, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, Laurent A. Decosterd, Ian Parsons, Lewis Pannell, James B. McMahon, Gordon M. Cragg
-
Patent number: 5591770Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.Type: GrantFiled: May 21, 1993Date of Patent: January 7, 1997Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of IllinoisInventors: Michael R. Boyd, John H. Cardellina, II, Kirk R. Gustafson, James B. McMahon, Richard W. Fuller, Gordon M. Cragg, Yoel Kashman, Doel Soejarto